# Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

> **NCT00004929** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** MUC-2-KLH vaccine
- **BIOLOGICAL:** QS21

## Key facts

- **NCT ID:** NCT00004929
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004929, "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*